No Data
Express News | Jazz Pharmaceuticals PLC - Expects to Meet 2024 Revenue Guidance
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Zymeworks Says It Has Enough Cash to Operate Through H2 2027
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Delivered A Weaker ROE Than Its Industry
Jefferies Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $170
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)